These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Comparison of the analgesic efficacy and safety of nepafenac ophthalmic suspension compared with diclofenac ophthalmic solution for ocular pain and photophobia after excimer laser surgery: a phase II, randomized, double-masked trial. Colin J, Paquette B. Clin Ther; 2006 Apr; 28(4):527-36. PubMed ID: 16750464 [Abstract] [Full Text] [Related]
9. Pupil dilation with intracameral lidocaine during phacoemulsification. Nikeghbali A, Falavarjani KG, Kheirkhah A, Bakhtiari P, Kashkouli MB. J Cataract Refract Surg; 2007 Jan; 33(1):101-3. PubMed ID: 17189802 [Abstract] [Full Text] [Related]
10. A randomized comparison of to-aqueous penetration of ketorolac 0.45%, bromfenac 0.09% and nepafenac 0.1% in cataract patients undergoing phacoemulsification. Bucci FA, Waterbury LD. Curr Med Res Opin; 2011 Dec; 27(12):2235-9. PubMed ID: 21992076 [Abstract] [Full Text] [Related]
11. Role of topical nepafenac in prevention and treatment of macular edema after vitreoretinal surgery. Naithani P, Puranik S, Vashisht N, Khanduja S, Kumar S, Garg S. Retina; 2012 Feb; 32(2):250-5. PubMed ID: 21926942 [Abstract] [Full Text] [Related]
12. Prednisolone and flurbiprofen drops to maintain mydriasis during phacoemulsification cataract surgery. Shaikh MY, Mars JS, Heaven CJ. J Cataract Refract Surg; 2003 Dec; 29(12):2372-7. PubMed ID: 14709299 [Abstract] [Full Text] [Related]
13. Once-daily nepafenac ophthalmic suspension 0.3% to prevent and treat ocular inflammation and pain after cataract surgery: phase 3 study. Modi SS, Lehmann RP, Walters TR, Fong R, Christie WC, Roel L, Nethery D, Sager D, Tsorbatzoglou A, Philipson B, Traverso CE, Reiser H. J Cataract Refract Surg; 2014 Feb; 40(2):203-11. PubMed ID: 24345529 [Abstract] [Full Text] [Related]